Skip to content
DraconiticResearch
Search Sources API
197,785 studies31 sourcesUpdated 21 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors

  • Justin Moser1
  • Igor Puzanov2
  • Hans Hammers3
  • Sunandana Chandra4
  • Martin Gutierrez5
  • Rohan Maniar6
  • Kristin Morris7
  • Amir Steinberg8
  • Saero Park9
  • Ismael Rodriguez Rivera10
  • Brendan D Curti11
  • Ahmad A Tarhini12
6 more authors
  • Kulandayan K Subramanian7
  • Matt Chapman-Rounds13
  • Randi E Isaacs7
  • Sameer S Chopra7
  • Mehmet A Bilen14
  • Jennifer M Segar15
15 affiliations
  1. 11Honor Health, Scottsdale, AZ, USA
  2. 225 Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
  3. 3University of Texas Southwestern Medical Center, Dallas, TX, USA
  4. 46Northwestern University, Chicago, IL, USA
  5. 5Hackensack University Medical Center Center, Hackensack, New Jersey, USA
  6. 61 Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York, USA
  7. 7Werewolf Therapeutics Inc., Watertown, MA, USA
  8. 8Hematology, New York Medical College, Valhalla, New York, USA
  9. 910Werewolf Therapeutics, Reading, MA, USA
  10. 10NEXT Oncology, San Antonio, TX, USA
  11. 11Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA
  12. 12H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
  13. 13Cogitars GmbH, Heidelberg, Baden-Württemberg, Germany
  14. 14Winship Cancer Institute of Emory University, Atlanta, GA, USA
  15. 15Texas Oncology-Houston Medical Center Next Oncology, Houston, TX, USA
Open at sourcePDFDOICite

Related

  1. 1193 Analysis of a Phase II trial with GT103 in combination with pembrolizumab in refractory, advanced stage non–small cell lung cancer
    Hirva Mamdani, Ryan Gentzler, Frank Weinberg +3
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  2. Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST: A Case Report
    Neharika Bandaru, Job Shiach, Mark Agulnik
    Cancer ReportsPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  3. Garsorasib (D-1553) in Combination With Pembrolizumab and Chemotherapy for First-Line Metastatic NSCLC With KRAS G12C Mutation: Results of a Phase 1b Study.
    Dong Yan, Chaoying Liu, Xingya Li +10
    JTO clinical and research reportsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  4. Immunotherapy with Pembrolizumab beyond Progression and Local Ablative Therapy in Oligoprogressive Metastatic Non-Small Cell Lung Cancer
    Anton Oseledchyk, Leopold Häcker, Andreas Michael Schmitt +4
    Oncology Research and TreatmentPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  5. Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
    Jordi Remon, Paolo Bironzo, Nicolas Girard +17
    Lancet OncologyPeer-reviewedLicence not statedFull text14 citedNeurologyHAL

Cite

BibTeXRIS
BibTeX
@article{moser20261189,
  title = {{1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors}},
  author = {Justin Moser and Igor Puzanov and Hans Hammers and Sunandana Chandra and Martin Gutierrez and Rohan Maniar and Kristin Morris and Amir Steinberg and Saero Park and Ismael Rodriguez Rivera and Brendan D Curti and Ahmad A Tarhini and Kulandayan K Subramanian and Matt Chapman-Rounds and Randi E Isaacs and Sameer S Chopra and Mehmet A Bilen and Jennifer M Segar},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.1189},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.1189},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors
AU  - Justin Moser
AU  - Igor Puzanov
AU  - Hans Hammers
AU  - Sunandana Chandra
AU  - Martin Gutierrez
AU  - Rohan Maniar
AU  - Kristin Morris
AU  - Amir Steinberg
AU  - Saero Park
AU  - Ismael Rodriguez Rivera
AU  - Brendan D Curti
AU  - Ahmad A Tarhini
AU  - Kulandayan K Subramanian
AU  - Matt Chapman-Rounds
AU  - Randi E Isaacs
AU  - Sameer S Chopra
AU  - Mehmet A Bilen
AU  - Jennifer M Segar
PY  - 2026
DA  - 2026/11/08
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.1189
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.1189
SN  - 2051-1426
ER  -